Company overview
Obatala Sciences provides human-derived hydrogels for 2D and 3D cell culture, organ-on-a-chip models, and adipose tissue engineering tools like the ObaCell platform for research in obesity, diabetes, cancer, and regenerative medicine. Their offerings include customized stem cell isolation services from human or animal tissues and fully humanized microphysiological systems to advance drug development. Based in New Orleans, the company emphasizes diversity in biotechnology research models.
Obatala Sciences is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include organ-on-a-chip, human-derived hydrogel, adipose tissue engineering, obacell platform, stem cell services.
Structured facts
- Website
- https://www.obatalasciences.com
- Markets served
- United States & Americas
- Keywords
- organ-on-a-chip, human-derived hydrogel, adipose tissue engineering, obacell platform, stem cell services
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What are Obatala Sciences' main products for pharma R&D?
- Key offerings include human-derived hydrogels for 2D/3D cell culture, ObaCell obesity-on-a-chip platform, and custom stem cell isolation services such as SVF, ASC, BMSC, and DFC from human or animal tissues.
- What research areas does Obatala Sciences support?
- They focus on obesity, diabetes, cancer, orthopedic conditions, tissue engineering, and regenerative medicine through adipose-derived models and organ-on-a-chip technologies.
- Does Obatala Sciences offer services for diverse human models?
- Yes, their platforms create human cellular tissue models embracing diversity across ethnicity, age, and gender to improve accuracy in drug development research.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
